Promising drugs and treatment options for pediatric and adolescent patients with Hodgkin lymphoma

Currently-available therapies for newly-diagnosed pediatric and adolescent patients with Hodgkin lymphoma result in >95% survival at 5 years. Long-term survivors may suffer from long-term treatment-related side effects, however, so the past 20 years have seen clinical trials for children and adol...

Descripción completa

Detalles Bibliográficos
Autores principales: De Re, Valli, Repetto, Ombretta, Mussolin, Lara, Brisotto, Giulia, Elia, Caterina, Lopci, Egesta, d’Amore, Emanuele S. G., Burnelli, Roberta, Mascarin, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729954/
https://www.ncbi.nlm.nih.gov/pubmed/36506094
http://dx.doi.org/10.3389/fcell.2022.965803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729954/
https://www.ncbi.nlm.nih.gov/pubmed/36506094
http://dx.doi.org/10.3389/fcell.2022.965803

Ejemplares similares